Disc Medicine, Inc. (IRON) News
Follow Disc Medicine, Inc. (IRON) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 31 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Disc Medicine Reports Quarterly Results for Quarter Ended September 30
EQUITY | Nov 05, 2026, 04:54 PM UTC
M
Disc Medicine Shares Fall More Than 2% After Q3 Results
Disc Medicine shares were more than 2% lower after its third-quarter results.
EQUITY | Nov 05, 2026, 03:26 PM UTC
M
Disc Medicine Reports Third-Quarter 2026 Financial Results
Disc Medicine reported third-quarter 2026 financial results and provided a business update.
EQUITY | Nov 05, 2026, 01:45 PM UTC
M
Disc Medicine Reports Third-Quarter 2026 Results and Business Update
Disc Medicine said its pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria successfully met a
EQUITY | Nov 05, 2026, 01:33 PM UTC
M
Disc Medicine Raises $450 Million in Public Offering
Disc Medicine agreed to sell 6 million common shares at $75 each, with expected net proceeds of approximately $422.4 million. Underwriters have a 30-day option to purchase up to 900,000 additional shares.
EQUITY | Oct 22, 2026, 09:13 PM UTC
M
Disc Medicine Prices Upsized $450 Million Public Offering of Common Stock
EQUITY | Oct 21, 2026, 12:59 AM UTC
M
Disc Medicine Says Phase 3 Bitopertin Trial Met All Endpoints
Disc Medicine said its Phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints. The company plans to resubmit its NDA by the end of 2026, with an FDA decision expected by mid-2027.
EQUITY | Oct 20, 2026, 01:00 PM UTC
M
Five Stocks Draw Attention After Earnings, Trial Results and Merck Deal
Cleveland-Cliffs reported third-quarter adjusted EPS of 28 cents and projected fourth-quarter adjusted EBITDA of approximately $715 million. Disc Medicine reported positive Phase 3 results, Merck agreed to acquire Silenc
EQUITY | Oct 20, 2026, 01:04 AM UTC
L
Disc Medicine proposes $350 million public offering
Disc Medicine announced a proposed $350 million public offering of common stock and pre-funded warrants.
EQUITY | Oct 19, 2026, 08:05 PM UTC
M
Disc Medicine Late-Stage Trial Win Clears Path to Resubmit Approval Application
Disc Medicine said its experimental pill for a rare disease helped patients spend more time in sunlight without pain. The company can resubmit its application; shares rose 35% in early trading.
EQUITY | Oct 19, 2026, 04:23 PM UTC
M
Disc Medicine Shares Rise 39% on Positive Phase 3 Trial Results
Disc Medicine reported positive Phase 3 results for its erythropoietic protoporphyria treatment. Shares gained 39% to $78.88 on Monday and were roughly flat year to date.
EQUITY | Oct 19, 2026, 03:28 PM UTC
M
Disc Medicine Drug Meets Main and Secondary Goals in Late-Stage Trial
Disc Medicine said its experimental pill for a rare disease causing extreme pain from sunlight met all main and secondary goals in a late-stage trial. Shares surged 65% in premarket trading.
EQUITY | Oct 19, 2026, 12:05 PM UTC
M
Disc Medicine reports APOLLO Phase 3 trial success
The company says bitopertin met all primary and secondary endpoints in the pivotal APOLLO trial in adults and adolescents with erythropoietic protoporphyria.
EQUITY | Oct 19, 2026, 11:13 AM UTC
M
U.S. Stock Futures Rise as Bessent Attributes September Inflation to Energy Shock
U.S. stock futures rose Monday, with the Dow, S&P 500 and Nasdaq 100 higher. Treasury Secretary Scott Bessent said September’s hotter inflation reading reflects an “energy shock” and argued prices would ease after the Ir
EQUITY | Oct 19, 2026, 09:24 AM UTC
L
IRON: Promising data and efficient trial execution position both DISC-3405 and bitopertin for strong market entry
DISC-3405 shows promising efficacy and safety in PV, with rapid trial progress and potential for frontline use. Bitopertin's APOLLO phase III trial is well-powered and targets a rare disease market, with launch strategie
EQUITY | Sep 10, 2026, 01:14 PM UTC
L
Disc Medicine Price Target Maintained With a $100.00/Share by Wedbush
Ratings actions from Benzinga
EQUITY | Sep 10, 2026, 01:12 PM UTC
M
Disc Medicine reports Phase 2 DISC-3405 data from RESTORE-PV
Disc Medicine said initial Phase 2 RESTORE-PV data showed DISC-3405 controlled hematocrit and markedly reduced phlebotomy events.
EQUITY | Sep 10, 2026, 12:53 PM UTC
L
IRON: Promising late-stage data and strong market potential position both programs for significant impact
DISC-3405 shows promising efficacy and safety in PV, with plans for phase III and potential as a frontline therapy. Bitopertin's APOLLO phase III trial is well-powered, targeting a rare disease with significant unmet nee
EQUITY | Sep 10, 2026, 12:48 PM UTC
L
IRON - Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of H
IRON - Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
EQUITY | Sep 09, 2026, 11:25 PM UTC
L
IRON seen with multiple late-stage catalysts across hematology programs
TradingView reports upcoming late-stage catalysts for IRON, including phase III data for a bitopertin program in porphyria; Selcodebart data in myelofibrosis; and first patient data for DISC-3405 in polycythemia vera.
EQUITY | Sep 09, 2026, 02:29 PM UTC
M
Iron-focused red blood cell trial data and therapies eyed for catalysts
Bitopertin phase III data for red blood cell disorders is expected soon, with additional polycythemia vera data planned for SOHO. Expanded access and launch plans are underway.
EQUITY | Sep 09, 2026, 01:35 PM UTC
L
Disc Medicine maintained at Outperform by Wedbush
Wedbush maintained a Outperform rating on Disc Medicine, according to Benzinga ratings actions.
EQUITY | Sep 02, 2026, 12:47 PM UTC
L
Disc Medicine to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. NASDAQ:IRON, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patien
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
IRON - Disc Medicine to Participate in Upcoming Investor Conferences
IRON - Disc Medicine to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 12:01 PM UTC
L
IRON - Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - C
IRON - Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
EQUITY | Aug 31, 2026, 10:07 PM UTC
H
Truist Reiterates Buy On IRON
Truist reiterates buy rating on IRON
EQUITY | Jul 31, 2026, 01:00 PM UTC
M
IRON Disc Medicine Ends Q2 With $717.7M Cash
IRON Disc Medicine has $717.7M in cash and securities
EQUITY | Jul 30, 2026, 12:37 PM UTC
L
IRON - Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
IRON - Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Jul 30, 2026, 12:31 PM UTC
L
IRON Disc Medicine RESULTS: Q2, Q2 basic EPS $-1.54 vs. EST $-1.75, Q2 operating expenses $65.075M, Q2 Operating Income $-65.075M vs. EST $
IRON Disc Medicine RESULTS: Q2, Q2 basic EPS $-1.54 vs. EST $-1.75, Q2 operating expenses $65.075M, Q2 Operating Income $-65.075M vs. EST $-71M, Q2 Net Income $-59.532M vs. EST $-68.2M
EARNINGS | Jul 30, 2026, 12:31 PM UTC
L
Disc Medicine Insider Sold Shares Worth $2,473,780, According to a Recent SEC Filing
() -- John D Quisel, Director and Chief Executive Officer, on July 13, 2026, sold 33,000 shares in Disc Medicine (IRON) for $2,473,780. Following the Form 4 filing with the SEC, Quisel has control over a total of 226,064
REGULATION | Jul 15, 2026, 08:05 AM UTC
M
12 Health Care Stocks Move
Gainers Universe Pharmaceuticals (NASDAQ: UPC ) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi Therapeutics (NASDAQ: T
EQUITY | Jun 26, 2026, 11:20 PM UTC